Lipoprotein-associated phospholipase A2 and atherosclerosis

Current Opinion in Lipidology

Volumn 20, Issue 5, 2009, Pages 415-420

  Wilensky, Robert L ^a   Macphee, Colin H ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Acute coronary syndromes; Ischemic stroke; Lyso phosphatidylcholine; Macrophages; Myocardial infarction; Necrotic core

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; FATTY ACID; LIPOPROTEIN A; PHOSPHATIDYLCHOLINE;

ACUTE CORONARY SYNDROME; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; HEART INFARCTION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; LIPID METABOLISM; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; TISSUE NECROSIS; VASCULITIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; ENZYME INHIBITORS; HUMANS; OXIDATION-REDUCTION; PHOSPHOLIPIDS;

EID: 73349126414     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283307c16     Document Type: Review

References (38)

1. Khovidhunkit W, Kim M-S, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-1196.
2. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis. Circulation 2007; 116: 1832-1844.
3. Hansson GK. Atherosclerosis: an immune disease. The Anitschkov Lecture 2007. Atherosclerosis 2009; 202: 2-20.
4. Greaves DR, Gordon S. Recent insights into the biology of macrophage scavenger receptors. J Lipid Res 2005; 46: 11-20. (Pubitemid 40066666)
5. Zalewski A, Maophee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 9236-9931.
6. Reddy KJ, Singh M, Bangit JR, Batsell RR. The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review. J Clin Lipid 2009; 3: 85-93.
7. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vase Biol 2007; 27: 2094-2099. (Pubitemid 350287235)
8. Hou L, Chen S, Yu H, et al. Associations of PLA2G7 gene polymorphisms with plasma lipoproteln-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009; 125: 11-20.
9. Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 2009; 23: 73-83.
10. Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 2009; 23: 49-59.
11. Min JH, Jain MK, Wilder C, et al. Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase. Biochem 1999; 38: 12935-12942.
12. Stafforini DM, Sheller JR, Blackwell TS, et al. Release of free F2-lsoprostanes from esterifled phospholipids is catalyzed by intracellular and plasma plateletactivating factor acetylhydrolases. J Biol Chem 2006; 281: 4616-4623.
13. Davis B, Koster G, Douet LJ, et al. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J Biol Chem 2008; 283: 6428-6437.
14. Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine in atherosclerosis. Curr Med Chem 2007; 14: 3209-3220.
15. Gautier EL, Huby T, Witztum JL, et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 2009; 119: 1795-1804.
16. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vase Biol 2005; 25: 2255-2264. (Pubitemid 41552640)
17. Kim JY, Hyun YJ, Jang Y, et al. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Am J Clin Nutr 2008; 88: 630-637.
18. Lavi S, Herrmann J, Lavi R, et al. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Curr Atheroscler Rep 2009; 10: 230-235.
19. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vaso Biol 2006; 26: 2523-2529.
20. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002; 99: 13043-13048.
21. Kadl A, Boohkov VN, Huber J, Leitinger N. Apoptotic cells as sources for biologically active oxidized phospholipids. Antiox Redox Signal 2004; 6: 311-320. (Pubitemid 38332588)
22. Hazen SL Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. J Biol Chem 2008; 283: 11527-11531.
23. Wilensky RL, Y Shi Y, Mohler ER III, et al. Inhibition of lipoproteln-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development, Nat Med 2008; 14: 1059-1066.
24. Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118: 1172-1182.
25. Anderson JL Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008; 101: 23F-33F.
26. Daniels LB, Laughlin GA, Sarno MJ, et al. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 2008; 51: 913-919.
27. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondlabetio subjects. Arterioscler Thromb Vaso Biol 2007; 27: 1411-1416. (Pubitemid 46823453)
28. Tsimikas S, Willeit J, Knoflach M, et al. Lipoproteln-associated phospholipase AC activity, ferritin levels, metabolic syndrome and 10-yeard cardiovascular and nonoardlovasoular mortality: results from the Bruneck study. Eur Heart J 2009; 30: 107-115.
29. Sabatine MS, Morrow DA, O'Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscl Thromb Vasc Biol 2007; 27: 2463-2469.
30. Oldgren J, James SK, Siegbahn A, Wallentin L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 2007; 28: 699-704. (Pubitemid 46439239)
31. O'Donoghue MO, Morrow DA, Sabatine MC, et al. Lipoprotein-associated Phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in PROVE IT-TIMI 22 (Pravastatin Or atorVastatln Evaulatlon and Infection Therapy-Thrombolysls in Myocardial Infarction) Trial. Circulation 2006; 113: 1745-1752.
32. Oei H-HS, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam Study. Circulation 2005; 111: 570-575.
33. Nambi V, Hoogeveen RC, Chambless L, et al. Lipoprotein-associated phos- phollpase A2 and high-sensitivity C-reactlve protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2009; 40: 376-381.
34. Persson M, Berglund G, Nelson JJ, Hedblad B. Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a populationbased cohort study from Malmo, Sweden. Atherosclerosis 2008; 200: 191-198.
35. Elkind MS, Tai W, Coates K, et al. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 2009; 27: 42-50.
36. Mohler ER III, Sarov-Blat L, Shi Y, et al. Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature. Arterioscler Thromb Vasc Biol 2008; 28: 850-855.
37. Benson GM, Grimsditch D, Milliner K, et al. Antiatherosclerotlc effect of SB244323, a lipoproteln-associated phospholipase A2 inhibitor, in WHHL rabbits. Atherosclerosis 2000; 151: 66.
38. 2 activity and cardiovascular biomarkers in patients with stable coronary artery disease or coronary heart disease risk equivalent. J Am Coll Cardiol 2008; 51: 1632-1641.